Advertisement

Topics

Latest "POXEL" News Stories

20:13 EST 18th February 2019 | BioPortfolio

Here are the most relevant search results for "POXEL" found in our extensive news archives from over 250 global news sources.

More Information about POXEL on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about POXEL for you to read. Along with our medical data and news we also list POXEL Clinical Trials, which are updated daily. BioPortfolio also has a large database of POXEL Companies for you to search.

Showing "POXEL" News Articles, all 24

Extremely Relevant

Poxel licenses NASH project from DeuteRx

DeuteRx LLC granted Poxel SA exclusive global rights to DRX065, a Phase I candidate that Poxel intends to develop for nonalco...


Relevant

Poxel initiates second part of PXL065 study to treat NASH

Poxel has initiated the second part of the Phase Ia study of PXL065, which is being developed for the treatment...Read More... The post Poxel initiates second part of PXL065 study to treat NASH appeared first on Drug Development Technology.

Poxel closes enrolment in TIMES 2 trial of Imeglimin in Japan

French biopharmaceutical firm Poxel has concluded patient enrolment in the Phase III TIMES 2 clinical trial of its drug candidate...Read More... The post Poxel closes enrolment in TIMES 2 trial of Imeglimin in Japan appeared first on Drug Development Technology.


Poxel Adds To NASH Pipeline With Novel Single-Isomer Pioglitazone

Some ground-breaking chemistry has been used to produce a single isomer of pioglitazone, which has been acquired by France's Poxel...   

Deals this week: Biohaven Therapeutics, POXEL, Ossianix

Biohaven Therapeutics has signed a licensing agreement with AstraZeneca for a new drug candidate, AZD3241, targeting a rare neurodegenerative disease....Read More... The post Deals this week: Biohaven Therapeutics, POXEL, Ossianix appeared first on Drug Development Technology.

Poxel begins part 2 of phase 1a study for NASH treatment PXL065

This second part of the Phase 1a study will enroll six healthy subjects per group, with a primary objective to assess safety and tolerability and a secondary objective The post Poxel begins part 2 of phase 1a study for NASH treatment PXL065 appeared first on Pharmaceutical Business review.

Poxel Announces Participation at the H.C. Wainwright 20th Annual Global Investment Conference

POXEL S.A. (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), announced today that it will be featured as a presenting company at the H.C. Wainwright 20th Annual Global Investment Conference. ...

Poxel in €506m diabetes deal with Roivant Sciences

Management tracks: Real Endpoints, Poxel, Travecta

Poxel Announces Completion of Patient Enrollment for the TIMES 3 Trial in the Phase 3 ...

Read more...

Poxel Announces Completion of Patient Enrollment for TIMES 2 Trial in Phase 3 Registration ...

Read more...

Poxel Appoints Takashi Kaneko, MD, PhD, as Senior Vice President Medical and President of Poxel Japan K.K.

Poxel has also established a Japanese subsidiary in Tokyo Both events are strategic commitments to the Japanese and Asian markets POXEL SA (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including

Poxel SA POXEL Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 24092018] Prices from USD $250

SummaryPoxel SA Poxel is a biopharmaceutical company that develops and markets drugs for metabolic diseases. The company's products comprise imeglimin, AMPK, GLP1, FXR, 11BHSD1 and GKA. Its imeglimin targets mitochondrial dysfunction. Poxel also offers inlicensing of its products. The company's PXL770 directly activates adenosine monophosphateactivated protein kinase that controls wholebody energy...

Probably Relevant

Poxel Presents Promising Data for PXL770 and PXL065 for the Treatment of NASH at the American Association for the Study of Liver Diseases Meeting

PXL770 was shown to have a beneficial effect on both the adipose tissue and liver through direct activation of AMPK in a DIO-NASH model PXL065 data suggests the potential for similar efficacy with a reduced side effect profile from pioglitazone for NASH POXEL SA (Euronext: POXEL - FR0012432516), a

Poxel Announces Completion of Patient Enrollment for the TIMES 3 Trial in the Phase 3 Registration Program for Imeglimin, an Investigational Therapeutic Agent for Type 2 Diabetes, in Japan

Phase 3 TIMES data readout is on track for 2019 Japanese New Drug Application submission for Imeglimin targeted in 2020 Diabetes is a fast-growing market in Asia and Japan is the second largest single market for type 2 diabetes outside of the U.S.; it is expected to grow to approximately $6 billion in 20201 ...

Poxel Announces Completion of Patient Enrollment for TIMES 2 Trial in Phase 3 Registration Program for Imeglimin, an Investigational Therapeutic Agent for Type 2 Diabetes, in Japan

Phase 3 TIMES 1, TIMES 2 and TIMES 3 trials for Imeglimin are now fully enrolled with over 1,100 patients Phase 3 TIMES data results are on track for 2019 Japanese New Drug Application submission for Imeglimin targeted in 2020 Diabetes is a fast-growing market in Asia and Japan is the second ...

Poxel Announces Presentation of PXL065 Data at the 2019 NASH-TAG Conference

Presentation highlighted different stereoisomer properties of pioglitazone and other thiazolidinediones (TZDs) Data observed suggests a more favorable profile for PXL065 versus pioglitazone and other TZDs for the treatment of NASH POXEL SA (Euronext: POXEL – FR0012432516), a biopharmaceutical company

Poxel Announces Initiation of Part 2 of Phase 1a Study for PXL065, which is being Developed for the Treatment of NASH

PXL065 data to date suggest the potential for a favorable profile for the treatment of NASH POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including

Poxel Presents Complete PXL770 Phase 1 Results, Cardiac Safety Profile and Preclinical Efficacy Data in NASH at AMPK - From Mechanisms to New Therapies Scientific Congress

Phase 1 clinical program for PXL770 was observed to have a favorable pharmacokinetic, tolerability and safety profile PXL770 was observed to have a favorable cardiac safety profile in both healthy subjects and in animal models PXL770 was observed to show efficacy in a diet-induced obese-NASH mice model ...

Poxel Announces Third Quarter and Nine Months 2018 Financial Update

POXEL SA (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced its cash posi

Poxel Expands Metabolic Pipeline Through Strategic Acquisition Agreement with DeuteRx for DRX-065, a Novel Clinical Stage Drug Candidate for NASH, and Other Programs

Poxel acquires exclusive, worldwide ownership to DRX-065 (deuterium-stabilized R-pioglitazone), a clinical stage program being pursued for the treatment of NASH Additional programs, including deuterated drug candidates for metabolic, specialty and rare diseases, also acquired from DeuteRx Poxel plans to advance ...

Poxel Announces Fourth Quarter and Full Year 2018 Financial Update

POXEL SA (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced its cash position and revenue for the fourth

Poxel Reports Financial Results for the First Half 2018 and Provides Corporate Update

Executed strategic agreement for Imeglimin with Roivant Sciences, which included USD 35 million upfront payment, and potential for up to USD 600 million in regulatory and development milestone payments and sales-based payments plus royalties on net sales Roivant concurrently invested USD 15 million in Poxel through subscript...

Possibly Relevant

ENYO Pharma Announces the Successful Completion of Phase Ib with Its FXR Agonist EYP001 and the Start of Phase II Studies in Two Indications, NASH and HBV

ENYO Pharma’s Phase Ib clinical study confirmed the safety and tolerability of its drug candidate EYP001 in chronic hepatitis B patients. Phase II clinical studies with EYP001 are planned to start in Q4 2018 for NASH and in Q1 2019 for chronic Hepatitis B. ENYO Pharma, a clinical stage biotech company developing i...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks